http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 24 Jul 2026 06:09:19 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/BTIG+Reiterates+Buy+Rating+on+Perspective+Therapeutics+Inc+%28CATX%29/26810144.html <p>BTIG analyst Jeet Mukherjee reiterated a Buy rating and $14.00 price target on Perspective Therapeutics Inc (NYSE: CATX).</p><p>The analyst commented: "We hosted Perspective Therapeutics for a series of investor meetings and came away with increased conviction in CATX as a 2H26 Top Pick. A consistent standout across meetings was a lack of appreciation for CATX's end-to-end Pb-212 manufacturing infrastructure that we believe is a widening competitive moat that carries value well above what the market is ascribing today. On the clinical side, VMT-a-NET remains on track for ph 3 initiation before EOY, with ph 1/2 responses deepening well after the http://www.streetinsider.com/Analyst+Comments/BTIG+Reiterates+Buy+Rating+on+Perspective+Therapeutics+Inc+%28CATX%29/26810144.html Fri, 24 Jul 2026 06:09:19 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26790522.html si-local-file:///var/storage/secattach/20260720/26790522.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26790522.html Mon, 20 Jul 2026 17:24:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26790522.html si-local-file:///var/storage/secattach/20260720/26790522.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26790522.html Mon, 20 Jul 2026 17:24:00 -0400 CATX O.00064612 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Corporate+News/Perspective+Therapeutics+names+new+chief+science+officer/26743954.html <p>Perspective Therapeutics (NYSE American: CATX) announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer, replacing co-founder Michael K. Schultz, Ph.D., who has transitioned to the role of Senior Scientific Advisor & Co-Founder as part of a planned move toward retirement.</p><p>Dr. Lyne brings more than 25 years of pharmaceutical and biotechnology experience, including roles in target discovery, drug discovery, early clinical development, and portfolio strategy. He most recently served as Senior Vice President and Head of Oncology Research at Merck KGaA, where he led a global research organization covering cancer cell signaling, immuno-oncology, and antibody-drug conjugates. During his career, http://www.streetinsider.com/Corporate+News/Perspective+Therapeutics+names+new+chief+science+officer/26743954.html Wed, 08 Jul 2026 06:33:44 -0400 CATX http://www.streetinsider.com/Management+Changes/Perspective+Therapeutics+names+new+chief+science+officer/26743954.html <p>Perspective Therapeutics (NYSE American: CATX) announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer, replacing co-founder Michael K. Schultz, Ph.D., who has transitioned to the role of Senior Scientific Advisor & Co-Founder as part of a planned move toward retirement.</p><p>Dr. Lyne brings more than 25 years of pharmaceutical and biotechnology experience, including roles in target discovery, drug discovery, early clinical development, and portfolio strategy. He most recently served as Senior Vice President and Head of Oncology Research at Merck KGaA, where he led a global research organization covering cancer cell signaling, immuno-oncology, and antibody-drug conjugates. During his career, http://www.streetinsider.com/Management+Changes/Perspective+Therapeutics+names+new+chief+science+officer/26743954.html Wed, 08 Jul 2026 06:33:44 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jul+01/26720737.html si-local-file:///var/storage/secattach/20260701/26720737.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jul+01/26720737.html Wed, 01 Jul 2026 16:11:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jul+01/26720737.html si-local-file:///var/storage/secattach/20260701/26720737.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jul+01/26720737.html Wed, 01 Jul 2026 16:11:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26715024.html si-local-file:///var/storage/secattach/20260630/26715024.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26715024.html Tue, 30 Jun 2026 17:37:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26715024.html si-local-file:///var/storage/secattach/20260630/26715024.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26715024.html Tue, 30 Jun 2026 17:37:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jun+01/26578653.html si-local-file:///var/storage/secattach/20260601/26578653.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jun+01/26578653.html Mon, 01 Jun 2026 06:31:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jun+01/26578653.html si-local-file:///var/storage/secattach/20260601/26578653.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jun+01/26578653.html Mon, 01 Jun 2026 06:31:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+27/26558193.html si-local-file:///var/storage/secattach/20260527/26558193.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+27/26558193.html Wed, 27 May 2026 16:20:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+27/26558193.html si-local-file:///var/storage/secattach/20260527/26558193.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+27/26558193.html Wed, 27 May 2026 16:20:00 -0400 CATX O.00064612